Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response-Reference-Cited by-同舟云学术

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

Published:2012-11 Issue:11 Volume:18 Page:2026-2033
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Katz Lior,Gisbert Javier P.,Manoogian Beth,Lin Kirk,Steenholdt Casper,Mantzaris Gerassimos J.,Atreja Ashish,Ron Yulia,Swaminath Arun,Shah Somal,Hart Ailsa,Lakatos Peter Laszlo,Ellul Pierre,Israeli Eran,Svendsen Mads Naundrup,van der Woude Janneke C.,Katsanos Konstantinos H.,Yun Laura,Tsianos Epameinondas V.,Nathan Torben,Abreu Maria,Dotan Iris,Lashner Bret,Brynskov Jorn,Terdiman Jonathan P.,Higgins Peter D.R,Chaparro Maria,Ben-Horin Shomron

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference19 articles.

1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

2. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease

3. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

4. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease

5. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study;BioDrugs;2024-08-22

2. Changes in the intensified regimen of infliximab in patients with inflammatory bowel disease in sustained remission: Reflections on a series of cases;Gastroenterología y Hepatología (English Edition);2024-08

3. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

4. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

5. Optimal Management of Refractory Crohn’s Disease: Current Landscape and Future Direction;Clinical and Experimental Gastroenterology;2024-03